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Abstract 
Stem cell-based therapy has shown great promise as a strategy to treat a number of 
neurodegenerative diseases and injuries (Lindavall et. Al., 2006). Neurodegenerative diseases 
refer to a range of different conditions that result from the death and/or degeneration of neurons 
(College, 2014). Some common neurodegenerative diseases include Alzheimer’s disease, 
Parkinson’s disease, Spinal Muscular Atrophy, Huntington’s disease, Amyotrophic Lateral 
Sclerosis, and Spinocerebellar Ataxia (Medicine, 2000). However, currently only 5-10% of 
implanted neural stem cells (NSCs) survive the initial immune response. It has been 
demonstrated that transplanted NSCs encapsulated in hydrogel have a higher survival rate (Yang 
et. al., 2014). Therefore, a microfluidic device was designed to encapsulate live cells in microgel 
spheres;using a microfluidic device allowed for high-throughput encapsulation of the NSCs, as 
well as the production of uniform microgel spheres. Specifically, a flow-focusing microfluidic 
device was used for its ability to produce a more consistent microgel sphere size as compared to 
other devices, such as the T-junction. Hyaluronic acid (HA) was used as the encapsulating 
hydrogel. HA is a natural polymer found in the central nervous system (CNS) and has anti-
inflammatory properties. Irgacure 2959 was chosen as the photoinitiator so that the microgel 
spheres could be photocrosslinked as they moved through the channels of the microfluidic 
device. Photocrosslinking of the HA was activated using an ultraviolet lamp. A protocol for cell 
encapsulation was developed in order to successfully encapsulate live cells in the microgel 
spheres. Once the protocol for microgel sphere formation was optimized, Jurkats cells, U87MG 
cells, or PC12 cells were cultured and were used to test for encapsulation within the microgel 
spheres. After collection of the spheres, they were stained with calcein and/or ethidium 
homodimer for cell viability analysis using a fluorescence microscope. The data collected shows 
that the developed system is able to create microgel spheres in the range of 50-70 μm that can 
encapsulate cells. However more testing is needed in order to validate the microfluidic design 
and encapsulation protocol. In addition, further optimization is suggested so as to improve the 
encapsulated cells’ viability.  
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Chapter 1 – Introduction 
Neurological diseases and injuries affect millions of people worldwide. Alzheimer’s 
disease is the most common cause of age related cognitive degeneration and affects 12 million 
people worldwide, while Parkinson’s disease affects 6 million people worldwide (Aarli et. al., 
2006). Neurodegenerative diseases affect the metal ability of the patient to the point where it 
interferes with their daily life. Spinal cord injury (SCI) is a debilitating condition that affects 
millions of people worldwide and typically results in complete or partial paralysis. In the US alone, 
there are 12,000 new cases per year in addition to the 232,000-316,000 people already living with 
SCI (The National Spinal Cord Injury Statistical Center, 2011). These injuries are often irreversible 
and result from a variety of causes such as traffic accidents, acts of violence, falls, and sports 
injuries. Most SCIs occur when a fractured vertebra or disk intrudes the spinal canal, causing 
complete or incomplete severing of the spinal cord. While there are various degrees of contusion, 
laceration, and complete transection, the main issue associated with SCI is regeneration because 
the central nervous system (CNS) is not capable of spontaneous regeneration (Madigan et. al, 
2009). The pathophysiology of SCI is unknown so current treatments, such as steroids, only 
address the symptoms of mechanical compression and acute inflammation without repairing the 
site of injury. 
Current treatments for neurological diseases and injuries include drug therapy and stem 
cell therapy. Drug therapy is designed to target the various components of cognitive, memory, and 
movement disorders, while stem cell therapy is used to target injured tissue and promote functional 
recovery as well as preserve function in the brain and spinal cord (Aarli et. al., 2006). However, 
current pharmacological approaches are limited, as they offer transient benefits to the afflicted and 
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do not significantly modify the course of the condition. Stem cell therapies also have limitations, 
as proliferation and differentiation of the implanted stem cells into the desired cellular phenotypes 
must be controlled to prevent tumor formation. Furthermore, the mode of delivery affects the 
efficacy of stem cells to repair the damaged tissue. The mode of delivery is influenced by the 
pathological tissue environment, inflammatory, and immune reactions (Youdim & Buccafusco, 
2005). 
Only 5-10% of implanted stem cells survive the initial immune response. When foreign 
stem cells are implanted into a patient, the initial reaction of the body is to send T-Cells to the 
affected area. When T-Cells detect a foreign substance in the body, cytokines are released into the 
bloodstream to signal the presence of an unwanted body. Cytokine release triggers a cascade 
sending macrophages to the region, which destroy the foreign substance. Researchers need a way 
to prevent the body from destroying the implanted cells before they are able to integrate and 
become functional. The goal of this project was to design a microfluidic system that is capable of 
encapsulating mouse neural stem cells (NSCs) in biodegradable microgel spheres. 
The project began with a literature review on microfluidic devices, microgel sphere 
generators, NSCs, hydrogels, immune response, and causes of damage to the nervous system. A 
set of design criteria was created from the client statement, client meetings, and the literature 
review. These criteria were further expanded upon and organized into constraints, objectives, 
functions, and specifications. 
Initial designs were created in DraftSight and were based on the established constraints, 
specifications, and additional information provided by Professor Albrecht. The most important 
specifications taken into consideration when developing the initial device designs were microgel 
sphere size, channel size, and the number of cells per microgel sphere. By using these 
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specifications, the team was able to determine the proper channel width for optimum microgel 
sphere formation. The team used photolithography to make a silicon wafer as the master, which 
had the initial design options etched on. This silicon wafer was used as a template to transfer the 
designs to PDMS. The resulting PDMS microfluidic devices were tested to determine which 
designs generated microgel spheres that met the requirements and were fully crosslinked. The team 
picked the best design and developed a protocol for cell encapsulation. The microgel spheres were 
imaged to ensure that uniformly sized microgel spheres were formed and that the microgel spheres 
contained cells. 
At the conclusion of this project, a protocol for cell encapsulation and a flow focus 
serpentine microfluidic device capable of producing microgel spheres within the desired size range 
(50-70µm diameter) was modified and developed. Although this system and corresponding 
protocols require further optimization and experimentation, it shows promise. Once optimized, 
this system can be applied not only to encapsulating NSCs for neurological cell therapy, but also 
to other cell types. This technology has the potential to revolutionize current stem cell therapy 
practices. 
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Chapter 2 – Literature Review 
2.1 – Current Neural Stem Cell Treatments 
Unlike most tissues in the body, the neural system has a limited capacity for self-healing. 
Neural cells have a limited capacity to regenerate and the small populations of endogenous NSCs 
in brain tissue are unable to fully reconstitute and restore function after damage. As such, research 
has gone into developing potential cell replacement therapies to treat cerebral injury. There are 
many proposed stem cell therapies designed to address various neurodegenerative diseases. In each 
of these diseases, a different spectrum of cell types is affected; therefore, different types of neurons 
are required for replacement. There are three main sources of cells for replacement: neural tissue 
from fetuses, immortalized cell lines, and embryonic stem cells. The main goal of these treatments 
is to promote survival and functional integration (Kennea, Weston Laboratory, Mehmet, Weston 
Laboratory, & Weston Laboratory, 2014).  
Fetal neural cell transplantation has been used in several brain injury models to provide a 
source of immune-compatible cells for transplantation. One drawback is the supply of fetal neural 
tissue is limited and consequently only small numbers of neurons are available. This may be 
partially overcome by in vitro expansion. Immune rejection and subsequent failure of the graft can 
also be a problem, where there is poor graft survival and no clinical improvement. Lastly, there 
are ethical issues surrounding the use of fetal tissue, promoting the use of adult stem cells rather 
than those derived from fetal tissue. 
Immortalized cell lines have been employed in animal studies of brain injury resulting in 
histological integration and functional improvement. Immortalized cell lines have been used to 
treat demyelinating diseases through the transplantation of oligodendrocyte progenitor cells 
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(OPCs) that migrate away from the injection site to repopulate areas of demyelination. However 
immortalized cell lines are prone to tumorigenesis and they are unable to reconstitute the wide 
variety of cell types lost in cerebral injury. This makes them of only limited use in clinical 
applications. 
Embryonic stem cells are a promising alternative source of cells for therapeutic transfer. 
Embryonic stem cells are pluripotent, can be propagated in vitro, and can be engineered to express 
therapeutic genes. They can migrate and differentiate into regionally appropriate cell types, and 
do not interfere with normal brain development. 
In some NSC treatments the stem cells are genetically modified with other substances to 
improve the efficacy of the therapy. In a treatment of intracranial glioma, NSCs are modified to 
secrete interleukin 12 (IL-12). Gliomas are difficult to treat because the tumor exerts 
immunosuppressive effects at both the systemic and local intratumoral levels. In addition, 
malignant gliomas are highly invasive, which provides them with the ability to infiltrate deep into 
normal tissue, establishing microscopic reservoirs from which regrowth can occur after surgical 
resection. IL-12 is a potent tumoricidal cytokine with demonstrated efficacy against intracranial 
glioma. The combination of IL-12 with the extensive migratory and tumor tracking characteristics 
of NSCs, results in a vehicle capable of delivering IL-12 to neoplastic pockets separate from the 
main tumor mass (Ehtesham et al., 2002).  
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2.2 – Mouse Stem Cells 
2.2.1 – Differentiation Pathways 
Mammalian NSCs are capable of differentiating and replacing neurons that are lost or 
injured due to trauma or disease. The differentiation of NSCs occurs in stages and is controlled by 
cues from the cell microenvironment. 
All cells that make up the central nervous system (CNS) originate in the ventricular zone 
(VZ) from epithelial cells that have NSC properties. These cells are called neuroepithelial cells 
and are surrounded by extracellular matrix (ECM) molecules and signals, such as retinoic acid and 
fibroblast growth factors. These signals mediate cell-to-cell and cell-to-ECM interactions and 
trigger the neuroepithelial cells to divide in the VZ and form intermediate progenitors. Neurons 
are generated from the intermediate progenitor cells through neurogenesis. Neurogenesis occurs 
in two parts of the brain in adult mammals: the subventricular zone (SVZ) and the subgranular 
zone (SGZ).  The SVZ lines the lateral ventricles of the brain and is where the intermediate 
progenitors divide symmetrically to produce neurons and glia. From the SVZ, new neurons, or 
neuroblasts, migrate to the olfactory bulb, a neural structure in the forebrain. The SGZ is a subunit 
of the hippocampus; neuroblasts that form in the SGZ are integrated into the hippocampal 
formation ( Kazanis et al., 2008). 
 
2.2.2 – Differences Between Neurons and Glia Cells 
Mouse NSCs can be used to study the regeneration of neurons in humans. Neurons are 
electrically excitable cells that transmit signals to one another via synapses. Sensory neurons 
convey sensory information, such as feeling, to the brain or spinal cord. Motor neurons control 
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movement, and interneurons interconnect other neurons to form neural networks. On the other 
hand, glial cells are non-neuronal cells whose function is to provide support and protection for 
neurons and maintain homeostasis. The two types of glial cells that can differentiate from NSC are 
called astrocytes and oligodendrocytes (Purves et al., 2001). When transplanting NSCs into the 
body it is important to induce the right conditions for the desired type of cell to form, whether a 
neuron or a glial cell. One such condition is substrate or hydrogel stiffness. Researchers at the 
University of California Berkley discovered that optimal differentiation of NSCs into neurons 
occurred on substrates of intermediate stiffness and was approximately 500 Pa(Saha et al., 2008). 
The softer surfaces promoted neuronal differentiation while hard surfaces were found to favor glial 
differentiation (Banerjee et al., 2009). To ensure growth and renewal it is important to take 
precautions so that the cells survive the immune response that follows implantation.  
 
2.2.3 – Stem Cell Death Pathway 
The body’s immune response can be broken down into several stages. The first stage is 
antigen recognition in which antigen-presenting cells (APCs), such as macrophages and dendritic 
cells, bind fragments of antigenic peptides from the donor cells. APCs then present these fragments 
to helper T cells through the T cells’ antigen receptors.  The APCs express major histocompatibility 
complex (MHC) molecules because the antigen peptides must be presented in conjunction with an 
MHC molecule for the T lymphocytes to recognize and destroy the antigen peptides. The APC can 
be an allogeneic or one of the body’s own , autologous, depending on the donor cell death pathway. 
The activated helper T cells differentiate into effector cells and express cytokines and effector 
molecules on their membranes. When the cytokines or effector molecules are secreted, they act as 
growth and activation factors for cytotoxic T cells, B cells, and macrophages. The B cells mature 
Project BME-AJ1-1401 
16 
 
into plasma cells and secrete antibodies against the implanted cells, cytotoxic T cells trigger the 
apoptosis of the implanted cells, and macrophages initiate a delayed hypersensitivity inflammatory 
reaction (Sayegh & Turka, 1998).  
Many treatments have been evaluated in order to suppress the immune response to donor 
cells. One way to achieve immunosuppression is by utilizing cells found in immune privileged 
sites in the body. Immune privileged sites can be exposed to antigens without eliciting an 
inflammatory immune response. As a result, NSC and other tissue grafts transplanted in immune 
privileged sites can survive for extended periods of time without rejection. Immune privileged 
organs are among the few cells in the body that express a protein called Fas ligand. Fas ligand 
protects cells in immune privileged sites from invading inflammatory cells and can increase the 
survival rate of transplanted NSCs post-implantation (Gregory et al., 2002).  
 
2.3 – Hydrogels 
Cells and tissue used in regenerative medicine need to grow into a structure suitable for 
replacing the damaged tissue in the body. Scientists have been designing scaffolds to encapsulate 
the cells to ensure that they properly grow into the body. Hydrogels provide many distinct 
advantages for developing the scaffold; they allow transplanted cells to be immunoisolated while 
still allowing nutrients, and metabolic products to diffuse into their matrices, and their mechanical 
characteristics can be tailored to mimic those of natural tissues. The process of encapsulating cells 
in the hydrogel is simple, and once encapsulated, the hydrogel can adapt to the surrounding tissue 
in the body. The injection of these hydrogels is a minimally invasive procedure that makes it easy 
to administer the hydrogel into the patient. However, there are complications associated with this 
procedure that can make this procedure difficult. There are very few chemical crosslinking systems 
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currently available that are biocompatible, and physical crosslinking methods are difficult to 
trigger. In addition, physically crosslinked hydrogels have low stability in the body. Once the cells 
are encapsulated, providing them with adequate growth factors can prove to be difficult (Yang et 
al.). 
Despite these disadvantages, hydrogels are frequently used in tissue engineering for cell 
encapsulation purposes. The properties offered by hydrogels make them an excellent choice in 
material for cell encapsulation. Hydrogels have excellent permeability, which allows for the 
diffusion and transport of essential materials, such as oxygen and nutrients. Numerous 
biodegradable hydrogels have been developed for usage in drug delivery and cell scaffolding. Due 
to the three dimensional network structures of the hydrogels, and their viscoelasticity, hydrogels 
are useful scaffolds, allowing for cell adhesion, cell spreading, and cell proliferation. In addition, 
there is a lot of promise in the usage of hydrogels for the repair and regeneration of various tissues 
and organs (Yang et al.). 
 
2.3.1 – Factors in Hydrogel Selection 
When selecting a hydrogel for cell encapsulation, there are a number of factors that must 
be considered. These considerations are necessary to ensure that the cells survive the encapsulation 
process and continue to survive once encapsulated. The process of encapsulation or the transition 
of the solution from liquid to hydrogel must not place undue stress on the cells. Once the cells are 
encapsulated in the hydrogel, the structure of the hydrogel must allow cell growth and the hydrogel 
must properly degrade to allow the tissue to form. Other key factors that must be considered are 
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the products formed by the hydrogel upon degradation. Degradation products must be nontoxic 
and biocompatible, both to the cell culture and the patient (Nicodemus & Bryant, 2008).  
In addition, the liquid precursor solution used to suspend the cell culture must meet certain 
requirements as well. The components must be water soluble, as to properly mix with the cell 
solution. This solution must also be buffered with salts to prevent cell lysis within the solution 
(Nicodemus & Bryant, 2008).  
 
2.3.2 – Alginate 
Alginate is a polysaccharide containing a mixture of β-D-mannuronic acid and α-L-
guluronic acid. Alginate hydrogels are formed through ionotropic crosslinking, a process that is 
gentle on the cells and reversible. Some previous applications of this hydrogel have been found in 
wound dressing and food additives, but it has also shown a lot of promise in cell encapsulation. 
Alginate hydrogels have previously been used to encapsulate dorsal root ganglia and neural 
progenitor cells (Hunt & Grover, 2010). 
 
2.3.3 – Collagen 
Collagen is a protein found in almost all animals. It is the main structural protein that makes 
up connective tissues in animals and up to 30% of the total protein content in humans. By 
dispersing collagen in an acid, and then neutralizing it, one can form a collagen-based hydrogel 
that has a very high cell adhesion. Another appealing property of collagen-based hydrogels is that 
type I collagen hydrogels are able to self-assemble. The two major drawbacks to using collagen 
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based hydrogels is that they have weak mechanical properties and they contract when used to 
encapsulate cells (Hunt & Grover, 2010).  
 
2.3.4 – Fibrin 
Fibrin is a naturally occurring protein in the body that is used to form blood clots during 
wound closure. Fibrin gels form by proteolytic cleavage, caused by interaction with thrombin, 
exposing various regions on the protein that allow it to self-assemble. Fibrin gels are useful for 
cell encapsulation because they have regions that enable both cell adhesion and growth factor 
binding. The major drawback of these gels is that they rapidly degrade when encapsulating 
mammalian cells, due to the proteolytic enzymes that the cells secrete (Hunt & Grover, 2010).  
 
2.3.5 – Gelatin 
Gelatin is a molecule formed from the hydrolysation of collagen. Gelatin can be used to 
form hydrogels by dissolving the molecule into water at 60 °C, and then cooling to room 
temperature. Previous cell encapsulation experiments done with gelatin have been done for the 
encapsulation of chondrocytes and hepatocytes, cells from the cartilage and liver, respectively 
(Hunt & Grover, 2010).  
 
2.3.6 – Hyaluronic Acid 
Hyaluronic acid is a derivative of hyaluronan, a polysaccharide found through the body in 
the skin and cartilage tissues, among others. Hyaluronic acid is naturally found in the central 
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nervous system and is anti inflammatory. By modifying hyaluronic acid with thiols, methacrylates 
or tyramines the molecules can be chemically crosslinked to form a hydrogel. One of the key 
advantages of using hyaluronic acid is that the degradation of the hydrogel can be moderated by 
hyaluronidase, an enzyme secreted by a multitude of mammalian cells. These hydrogels have also 
been used for the encapsulation of dorsal root ganglia, a neural cell (Hunt & Grover, 2010). 
 
2.3.7 – Hydrogel Mixes 
 Many hydrogels are not made exclusively from a single type of polymer. Often the case is 
that the properties of the hydrogel can be improved by mixing multiple different polymers together 
to get a different type of hydrogel. Often the components are selected to complement each other’s 
properties. Below are two examples of hydrogels formed by fusing different compounds. 
 
2.3.7.1 – Chitosan-Gelatin 
 One popular hydrogel that is formed by combining different polymers is formed by mixing 
chitosan and gelatin. Chitosan is a deacetylated version of chitin, a protein that is found in the 
exoskeletons of insects and crustaceans. Structurally, chitosan mimics hyaluronic acid, which is a 
crucial component of the extracellular matrix. Chitosan has been shown to be blood compatible, 
and is used extensively in biomedical science. The chitosan-gelatin mix has been shown to be 
biocompatible and immunocompatible as well, when tested against macrophages (Risbud, Endres, 
Ringe, Bhonde, & Sittinger, 2001).  
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2.3.7.2 – Alginate-Chitosan  
Another popular hydrogel used for cell encapsulation is formed by a mixture of alginate 
and chitosan. Many different reactions are possible to form this hydrogel; in this paper two will be 
covered. The single stage procedure involves suspending the cell culture in 1.2% sodium alginate 
solution at a cell density of 1 X 106 cells/mL. The solution is then pushed through a microgel 
sphere forming device into a chitosan solution where they are allowed to form into a gel. The two 
stage procedure is similar to the single stage procedure, in which only the alginate is pushed into 
a calcium chloride solution for gel formation, and the microcapsules are reacted with chitosan to 
form a coating around them (Baruch & Machluf, 2006).   
 
2.4 – Hydrogel Crosslinking Methods 
The formation of a hydrogel occurs due to crosslinking between the individual polymer 
chains that make up the precursor of the polymer. During the crosslinking process, the polymer 
chains are connected by covalent, ionic, or physical bonds. These changes alter the physical state 
of the solution, changing it from a liquid to a gel state (Nicodemus & Bryant, 2008).  
Typically cells are suspended in a solution containing a gel precursor. This precursor must 
be water soluble, and buffered appropriately to prevent cell lysis. From here, the hydrogel is 
formed using radical chain polymerization or chemical crosslinking. These methods are used to 
generate covalently crosslinked hydrogels. Radical chain polymerization occurs when an initiator 
is present. The initiator reacts with the polymer to generate a free radical that moves through 
carbon-carbon double bonds to form covalently bonded chains. 
Chemical crosslinking methods have also been employed to encapsulate cells. These 
methods do not always require the presence of an initiator, though some require a precursor to 
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catalyze the reaction. There are many different chemical reactions used to form hydrogels, such as 
the well-known Michael Addition reaction. 
Crosslinking refers to the process of chemically joining two or more molecules by a 
covalent bond. Crosslinking reagents are molecules that contain two or more reactive ends that 
have the ability to chemically attach to certain functional groups on other molecules or proteins. 
The type of crosslinker chosen depends on their specificities for particular functional 
groups as well as other chemical properties that affect their behavior. The first property to consider 
when choosing a crosslinker is the crosslinker’s chemical specificity. Chemical specificity refers 
to the reactive ends of the crosslinker, and whether or not they are homobifunctional or 
heterobifunctional. Homobifunctional crosslinkers are molecules where the reactive ends are 
identical, whereas heterobifunctional crosslinkers have different reactive ends. It is also important 
to look at the spacer arm length of the crosslinker. The spacer arm length refers to the distance 
between conjugated molecules. The water solubility and permeability of the cell membrane of the 
crosslinker is important because it determines whether or not the crosslinker can permeate into 
cells as well as crosslink hydrophobic proteins within membranes. Lastly one should look at the 
spontaneously reactive or photoreactive groups in a crosslinker. This determines whether the 
crosslinker will react when it is added to a sample or if it can be activated through exposure to UV 
light (Hayworth, 2014).  
 
2.4.1 – Michael Addition 
Michael addition is a chemical crosslinking procedure that involves the addition of a 
carbanion or a nucleophile, such as a thiol or amine, to an unsaturated carbonyl compound. This 
procedure has previously been used to create PEG, collagen, heparin, and hyaluronic acid 
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hydrogels. When used in cell encapsulation, the procedure is as simple as suspending the cell 
culture in the polymer solution, and adding the precursor. Hydrogels such as Extracel have been 
formed by this method and are used in tissue engineering and drug delivery applications (Yang et 
al.).  
 
2.4.2 – Photopolymerization 
 There are two types of polymerization, step-growth polymerization and chain-growth 
polymerization. Step-growth polymerization is a type of polymerization where bi-functional or 
multi-functional monomers react to form first dimers, then trimers, then oligomers, and eventually 
long chain polymers. Chain-growth polymerization is the linking of molecules that incorporate 
double or triple carbon-carbon bonds. The monomers polymerized through chain-growth 
polymerization have the ability for their bonds to break and link with other monomers to create a 
chain (Stille, 1981). A type of chain-growth polymerization is photopolymerization. 
Photopolymerization occurs when visible or UV light interacts with light sensitive photoinitiators 
to create free radicals that initiate polymerization. Photopolymerization allows for spatial and 
temporal control of polymerization. It also allows for fast curing rates ranging from a few seconds 
to a few minutes at normal temperatures with little heat production. In terms of hydrogels, 
photopolymerization is minimally invasive to the hydrogel and therefore preferred (Nguyen & 
West, 2002).  
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2.5 – Methods and Devices for Microgel Sphere Generation 
2.5.1 – Electrospray 
Electrospraying is one of a few methods used to generate microgel spheres from various 
liquids and solutions, including cell suspension inside a hydrogel, in the micro to nano range 
(Young, Poole-Warren, & Martens, 2012). There are two variations of electrospray, electrospray 
in air and submerged electrospray (Young et al., 2012).  
Electrospray in air uses a capillary or needle, an electric potential, and a surface to create 
microgel spheres. A potential difference is created between the needle and a grounded electrode, 
charging the liquid in the needle (Hager & Dovichi, 1994; Suwan N Jayasinghe, Qureshi, & 
Eagles, 2006; Workman, Tezera, Elkington, & Jayasinghe, 2014). The flowing liquid exits the 
needle in a thin jet and disperses as it passes through an electric field, see Fig 3.a (Hager & Dovichi, 
1994; Suwan N Jayasinghe et 
al., 2006). Since the microgel 
spheres have the same charge 
they quickly separate and land 
on the designated surface. 
Microgel sphere size is 
controlled by flow rate, 
potential difference, and the liquid properties, such as viscosity (Workman et al., 2014). 
Electrospray in air has successfully been used to encapsulate cells in a synthetic hydrogel that 
caused no adverse effects to the cells in both blood monocyte and neuronal cell lines (Hager & 
Dovichi, 1994; Suwan N Jayasinghe et al., 2006). The cells showed no changes in shape, no 
alterations in mitosis, or other damage (Suwan N Jayasinghe et al., 2006).      
 
Fig. 3.a – Typical electrospray in air set-up (Ifa, Wu, Ouyang, & Cooks, 2010). 
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 Submerged electrospray is similar to electrospray in air, except the microgel spheres are 
dispersed in an insulating liquid instead of in air or a vacuum. This method of electrospray utilizes 
a syringe pump, a needle, an electric potential, an earth electrode, a UV light source, and an 
insulating liquid, specifically 
sunflower oil and surfactant, see 
Fig 3.b (Young et al., 2012). 
Similarly to electrospray in air, the 
charged liquid flows through the 
needle and exits in a jet. The earth 
electrode causes the jet to disperse 
microgel spheres into the insulating 
liquid. The microgel spheres are then polymerized by the UV light. Microgel sphere size is 
controlled by flow rate, potential difference, and the liquid properties. Submerged electrospray has 
successfully encapsulated cells in synthetic hydrogels with high viability (Young et al., 2012).  
 While the method of electrospraying liquids is well established, electrospraying cells is 
relatively new and has a few issues in need of solutions. A common issue with electrospraying of 
cells is its inability to evenly disperse cells within the microgel spheres, resulting in uneven nutrient 
absorption (Suwan N. Jayasinghe, 2011). Another issue, specifically for encapsulation of cells, is 
unstable jetting conditions caused by ion uptake in cells (Suwan N. Jayasinghe, 2011). 
Electrospraying is a viable option for cell encapsulation in a hydrogel but further research has to 
be conducted to resolve these issues and fully understand the effect on cells at a molecular level 
(Suwan N. Jayasinghe, 2011; Mongkoldhumrongkul, Swain, Jayasinghe, & Stürzenbaum, 2009). 
 
 
Fig. 3.b - Submerged electrospray schematic (Young et al., 2012) 
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2.5.2 – Microfluidic Devices 
Microgel sphere formation and size in microfluidic devices can be determined by 
controlling the geometry of the outlet and of the channel junctions. A microfluidic device can be 
designed with an expanding nozzle and/or T-junctions in the microfluidic channels. The expanding 
geometry in the nozzle would create a velocity gradient that precisely dictates the breakup location 
of the liquid thread, thereby allowing for control over the microgel sphere generation positioning 
and the breakup location of the microgel sphere. Microgel spheres are generated in T-junctions by 
controlling the inlet pressure or by dictating a constant flow rate using a pump. A drawback of 
using T-junctions is microgel sphere non-uniformity and instability (Piotr, Michael, Howard, & 
George, 2006) .  
Microgel sphere formation and size in microfluidic devices can be controlled by a 
piezoelectric actuator and/or electrostatic forces. A piezoelectric actuator can be used to convert 
electric voltage into mechanical translation to create a constant flow rate at the inlets, thereby 
enabling stable single microgel sphere formation. This method is useful for microgel sphere based 
micro-devices requiring synchronization and on demand generation. In addition, an electrostatic 
force can be used to generate microgel spheres. In this method, a high electric field pulse is applied 
on an oil-water interface, which charges the interface and causes microgel sphere formation. 
However this method is impractical for low cost simple devices and is unsuitable for cell 
encapsulation or diagnosis (Bransky, Korin, Khoury, & Levenberg, 2009).  
 
2.5.2.1 – Microgel sphere Formation 
The most common method for microgel sphere formation is through emulsion of two 
immiscible phases. Oil and water are common examples of this. Different types of oil phases are 
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commonly used. Hydrocarbons, silicones, and fluorinate oils are examples of different oil phases 
that can be used. Some examples of Hydrocarbon oils are hexadecane, vegetable oil, and mineral 
oil. Hydrocarbon oils are easily attainable and cheap, but are not usually compatible with cells. 
Silicone oils are also not a great option because they are not compatible with Polydimethylsiloxane 
(PDMS), which is a very common material for microfluidic devices. Fluorinate oils are the best 
option because they are biocompatible but are very expensive (Baret, 2012; Teh, 2008). 
 One does not necessarily have to use the oil phase; there are other aqueous phases that can 
be used. The important factor is that the phases are immiscible. It may be necessary to add 
surfactants to whatever phase is used in order to prevent the microgel spheres from coalescing or 
combining. Surfactants prevent the microgel spheres form combining by providing an energy 
barrier that stabilizes dispersion. Surfactants stabilize dispersion through steric repulsion of the 
surfactant molecules or surfactant gradients at the interface of the microgel spheres. The surfactant 
gradients at the microgel sphere interface results in what is referred to as the Marangoni effect. 
The Marangoni effect is when the surfactant distribution is non-uniform and leads to a gradient in 
surface tension, which creates a stress that opposes the flow (Baret, 2012).  
 The common and easiest method to form microgel spheres is when the dispersed phase is 
flowed through a microchannel as the flow from the immiscible liquid is independently flowed 
through a separate microchannel. These two phases end up meeting at a junction and shear stresses 
at the interface cause microgel spheres to form. Flow-focusing junctions as well as T-junctions are 
both designs used to facilitate the formation of microgel spheres. In the flow-focusing designs both 
phases are flowed through a narrower region where constriction allows for symmetric shearing 
which generates microgel spheres. In T-junctions an inlet channel containing one phase intersects 
a main channel that contains the other phase. Once they intersect shear forces and pressure 
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gradients force the inlet channel phase to elongate and eventually break into a microgel sphere. 
Changes to flow rates, channel dimensions, and relative viscosities can all alter the microgel 
spheres in terms of size and frequency (Teh, 2008).  
 
2.5.2.2 – Flow Control 
There are a couple of flow control methods that could be used for the microfluidic devices. 
The first method is through hydrostatic pressure. Hydrostatic pressure involves a reservoir, a 
priming syringe, a 3-way valve and tubing for the inlets and outlets of the microfluidic device. 
Hydrostatic pressure uses gravity to control flow. Some advantages to using hydrostatic pressure 
are that it is cheap and easy to set up, and its efficacy is easily altered by simply raising and 
lowering the height of the reservoirs. A disadvantage to hydrostatic pressure is that if the reservoirs 
are not monitored the flow may change. Another method of flow control is by using a syringe 
pump. Syringe pumps are useful because they are controlled by a computer and result in direct 
flow rate control. Some negative aspects of using a syringe pump is that it takes a considerable 
amount of time to maintain the flow rates desired and it also has a slow response to flow rate 
changes, so it is only useful for long periods of flow control. (Albrecht, 2014).  
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Chapter 3 – Project Strategy 
 The primary goal of this project was to design and fabricate a microfluidic device for NSC 
encapsulation. The purpose of this chapter is to explain the identified objectives and constraints 
associated with various components of the project. The initial client statement was revised after 
the group evaluated the objectives and constraints.   
 
3.1 – Client Statement 
 Professor Jain, the client, provided the following client statement to the team: 
To design and fabricate a microfluidic device that encapsulates neural stem cells in a 
biodegradable hydrogel capable of modulating the immune response to increase transplanted 
neural stem cell survival. 
After further research and discussion with Professor Jain, the team revised and refined the 
initial client statement to the following: 
Design and fabricate a microfluidic system that encapsulates neural stem cells in a biodegradable 
hydrogel capable of modulating the immune response to increase transplanted neural stem cell 
survival. 
The revised client statement was broken down into two main project aims:  
1. Design a microfluidic device that is capable of encapsulating mouse neural stem 
cells in biodegradable hydrogel microspheres 
2. Minimize the initial foreign body response of T-cells towards implanted neural 
stem cells 
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3.2 – Objectives 
 The client statement was broken down into three main project aims:  
1. Determine the hydrogel composition 
2. Determine and test photopolymerization mechanisms 
3. Design microfluidic devices using DraftSight® 
 
The team determined the hydrogel composition first because viscosity is a major 
determinant of the device design with respect to the channel dimensions. The team researched the 
various hydrogel options and discussed them with Professor Jain to determine the best option.  In 
addition to the hydrogel composition, the team determined the photopolymerizer as this effects the 
composition of the hydrogel and the length of time required to crosslink the hydrogel, ultimately 
affecting the geometry of the device. The team conducted a research and discussion process similar 
to that used for the hydrogel to determine the best photocrosslinker. The team broke down the third 
project aim, design a microfluidic device, into a series of primary and secondary objectives as seen 
in Fig. 4. 
Project BME-AJ1-1401 
31 
 
 
Fig. 4.  Design Objective Tree 
 The team needed to create a device that was reliable, precise, accurate, safe, usable, and 
had a reasonable cost.  
Reliability: The device would be used in lab by Professor Jain and had to be reliable. Reliability 
included a minimal level of maintenance, a reasonable lifespan, and easy and infrequent repairs. 
The time required to make the device had to be less than the total amount of time it was used in 
lab. The repairs had to be simple and replacement parts should be easily obtained, either 
commercially or in lab.  
Precision and Accuracy: The device had to be both precise and accurate so that the client would 
know the number of NSCs delivered in order to alter doses and accurately determine the interaction 
between the injected NSCs and the surrounding area, as well as the effect the NSCs would have 
on the surrounding area. A device that created uniformly-sized microgel spheres would help to 
evaluate the number of NSCs delivered. .  
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Safety: In terms of safety, the device had to be safe for the user to use as well as safe for the cells. 
User safety meant that no additional safety precautions were required outside of standard lab 
protocols when using the device. Cell safety meant that cells survived encapsulation and were not 
altered during the encapsulation process. All chemicals, light wavelengths, hydrogel viscosity and 
stiffness, and shear stresses had to be conducive to mouse NSC survival.  
Cost: The final cost of the device needed to remain low so that upkeep, maintenance, and 
replacement of supplies was feasible within Professor Jain’s working budget. Hydrogel and cell 
sources needed to be those already in Professor Jain’s lab.  
Usability: The last secondary objective was usability. The device setup needed to be quick and 
simple to learn, as the device would serve as tool in Professor Jain’s experiments and would not 
be the focus of the experiments.  
Professor Jain expressed that; precision, accuracy, cell safety, and usability were the top 
priority. 
 
3.3 – Constraints 
The team identified a series of constraints that the design could not violate based on the 
client statement and meetings with the client.  
 Time 
 Hydrogel source and type 
 Cell type 
 Device design  
 Cost 
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The first constraint was that the team had to design, construct, and test the device within 
one academic school year. Hydrogel options were constrained to those currently available in 
Professor Jain’s lab, such as collagen, chitosan, and hyaluronic acid. 
In addition to the above constraints, the design of the device had several constraints in order 
to produce a useable product.  The channels of the device designs had to be greater than 50 µm 
wide to prevent particulates and dust from clogging the channels and disrupting flow. The channels 
had to be more than 100 µm apart in order to prevent leakage of the fluid. The inlets had to be 1 
mm circles, spaced more than 2 mm apart, allowing the tubing to be easily inserted into the device. 
To allow for error when cutting out the PDMS, 3 to 4 mm of space had to be left around the edges 
of the device design, inlets, and outlet. There had to be a 5 mm border around the edge of the 4 in 
silicon wafer because spin coating leaves a thick layer of photoresist at the edge of the wafer. The 
thick layer is not exposed to the proper light intensity during the photolithography process, causing 
designs in those areas to not sufficiently imprint onto the wafer. Financial constraints and 
considerations are discussed in Section 3.4.  
 
3.4 – Financial Considerations 
The team had a budget of $780 provided by Worcester Polytechnic Institute (WPI). The 
client expressed that additional money was available if she deemed the purchase necessary. The 
majority of the team’s WPI budget was used for purchasing the photocrosslinker, components for 
photolithography, and printing the photomask.  
Photomask printing cost about $135 and the Irgacure photocrosslinker cost around $85/kg. 
The remainder of the budget was used for silicon wafers, tubing, syringes, and other supplies 
necessary for the construction of the device.   
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3.5 – Project Approach 
The goal of this project was to design and fabricate a microfluidic system that was capable 
of encapsulating cells. In order to do this, the literature was reviewed to determine which materials 
and device designs would be appropriate for use in this project. Experimental procedures 
determined which device was best to use, based on crosslinking time and the occurrence of 
microgel sphere coalescence. Further experimentation was used to refine the encapsulation 
protocol. Finally, fluorescence and bright field microscopy in combination with live/dead staining 
were used to evaluate the microgel sphere size distribution and cell encapsulation.    
There were some technical challenges that had to be overcome throughout this project. The 
first challenge was the team’s inexperience with microfluidics. The team had to learn the approach 
and techniques required to successfully design a microfluidic system. Equipment availability due 
to other researchers contributed to imaging delays. The major technical issue the team faced was 
device troubleshooting. During the experimental process, the device would clog either in the inlet 
because of premature hydrogel crosslinking or in the channels due to large Irgacure particles 
blocking channels. When the device clogged, the process had stop and restart so the device could 
be cleaned. This occurred frequently caused delays of up to an hour, or in some cases the device 
could no longer be used and the experiment had to stop until a new device was made.    
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Chapter 4 – Alternative Designs 
4.1 – Needs Analysis 
Stem cell-based therapy has shown promise in treating different neurological disorders and 
injuries.  Unfortunately only 5-10% of implanted NSCs survive the initial immune response. 
Transplanted NSCs that are encapsulated in a hydrogel have a higher survival rate. The use of 
microfluidics allows for encapsulation of NSCs in a hydrogel.  
 In order to effectively encapsulate NSCs in microgel spheres through microfluidics, many 
different design alternatives were created and evaluated. In order to evaluate these design 
alternatives, the functions and specifications were analyzed to determine the most effective design. 
 In order for the encapsulation of NSCs in microgel spheres to be effective it needed to 
satisfy the needs of the client, which were as follows: 
Reliability: The device had to require a minimum level of maintenance and a reasonable lifespan 
with infrequent repairs.  
Precision and Accuracy: The device had to be both precise and accurate so that the client could 
know the number of NSCs delivered in order to alter doses and accurately determine the effective 
therapeutic dose. Creating spheres of uniform size capable of encapsulating a consistent number 
of NSCs was also necessary. 
Safety: The device had to be safe for the user and safe for the cells. Therefore, the use of the device 
could not require additional safety precautions outside of standard lab protocols to be taken and 
cells had to survive the encapsulation process.  
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Cost: The upkeep, maintenance, and replacement of supplies for the microfluidic device had to be 
feasible for Professor Jain’s lab budget. It was thus preferred that hydrogel and cell sources be 
chosen from those already available in Professor Jain’s lab. 
Usability: The setup for the experimental process of encapsulating NSCs through the microfluidic 
device had to be user-friendly.  
 
4.2 – Functions 
To achieve the objectives specified by the client for this project, this project needed to 
achieve two main functions. The first main function of this project was the formation of microgel 
spheres used to encapsulate cells. The device used needed to be able to generate a steady stream 
of microgel spheres at a consistent size and diameter. Consistency between the microgel spheres 
was important for the therapeutic aspect of the project. 
The second main function of our device was crosslinking of the microgel spheres so that 
they maintain their shape upon removal from the device. In order to test these functions, the 
microgel spheres were observed under a fluorescent microscope. Two items were looked for 
during these tests. First, the group looked for the presence of fully formed microspheres, observed 
as dark circles in the solution. The second element the group looked for in the solution was the 
presence of cells within the microgel spheres. Observing cells under the microscope required the 
usage of fluorescent tagging in the cells prior to encapsulation. The group looked for the presence 
of fluorescent cell markings within the boundaries of the microspheres. 
To achieve the formation of microgel spheres the group decided to use a microfluidic 
microgel sphere generator. More specifically the group used a flow focusing device, which creates 
microgel spheres by directly injecting the discrete phase containing HA and cells into the 
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continuous phase containing the oil, surfactant, Irgacure, and solvent blue. Microgel spheres are 
formed through the compression of the discrete phase by the continuous phase. 
To achieve crosslinking, our group chose to use ultraviolet light crosslinking as our method 
for hardening the microgel spheres. HA does not naturally crosslink by exposure to ultraviolet 
light. This effect is obtained by adding Irgacure into the solution, which stimulates crosslinking. 
The primary alternative that was considered for the crosslinking step was to use a chemical 
crosslinker in our device. Alternatively, our group looked into the application of a Michael addition 
reaction to crosslink the microgel spheres.  The group decided to use photocrosslinking over 
chemical crosslinking because photocrosslinking allowed for better control over when crosslinking 
of the spheres occurred. 
Ultraviolet crosslinking poses a risk of cytotoxicity to the cells. The ultraviolet light can 
kill the cells if they are exposed to the light for an excessive amount of time. However, the cells 
exposure to ultraviolet light was limited to increase the cell viability. In addition, the Irgacure 
crosslinker the team added to the HA proved toxic to the cells. The cytotoxic effects of the Irgacure 
were minimized by adding the Irgacure to the continuous phase solution instead of including it in 
the discrete phase solution, separating it from the cells.  
 
4.3 – Conceptual Designs 
 The microfluidic chip the team used was made out of a polymer called 
polydimethylsiloxane (PDMS). There are multiple advantages to using PDMS for our microfluidic 
chip. PDMS allows for the ability to observe activity in the micro-channels under a microscope 
because it is transparent at a wide range of optical frequencies, 240nM-1100nM.  Next PDMS has 
a low autofluorescence making it a common polymer used in microfluidics involving photo-
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crosslinking. Also PDMS is easy to mold, allowing it to mold structures as small as a few 
nanometers. (PDMS: a review, 2015) 
 In terms of microfluidics there are two broad classes of microfluidic devices. The two 
classes of devices are t-junctions and flow focusing nozzles. Both of these classes have the 
capability to generate monodisperse particles as well as form emulsions of different sizes.  As you 
can see in Figure 5 below, a represents the T-junction class, and b represents the flow focusing 
junction class. In the T-junction the continuous phase is met by the discrete phase perpendicularly. 
With the flow focusing junction, the discrete phase is injected in between the continuous phase.  
(The role of feedback in microfluidic flow-focusing devices, 2015) Looking at studies done with 
both the t-junction and flow focus junction, the team found that the flow focusing junction would 
be more beneficial to this project. There are a couple of advantages to using the flow focus junction 
over the T-junction. The first being it has been seen that the flow focus junction produces a more 
consistent emulsion size than the T-junction. Another advantage to choosing the flow focus 
junction was because numerous studies involving microfluidics using photo-crosslinking. 
 
Fig. 5. A) T-junction device B) Flow-focusing device 
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Using a photoreactive group as the crosslinker in our gel allowed for immediate hardening 
of the gel once it would be exposed to ultraviolet light once the microgel spheres were formed. 
(Hayworth, 2014) 
 When looking at flow control there were two options available to us in our lab, hydrostatic 
pressure and syringe pumps. Hydrostatic pressure uses a difference in reservoirs to use gravity 
force to move the fluid from the inlet to the outlet. This method is useful for short periods of time 
because as the inlet reservoir is emptied and the outlet reservoir is filled the pressure difference 
changes. On the other hand, syringe pumps are perfect for low control over longer periods of time. 
The only drawback for our use of the syringe pump is that it takes 10 to 15 minutes for the syringe 
pumps to reach flow it is set to. Syringe pumps control the flow rate independent from fluidic 
resistance (Flow control in microfluidic devices, 2015). 
 
4.4 – Design Alternative Evaluation  
 Throughout the experiment alterations were made in order to optimize the protocol to better 
create microgel spheres that encapsulated cells. At first, HA was dispersed with Irgacure 2959 into 
well plates at different concentrations and exposed to UV (365 nm wavelength and 3.8 mW 
voltage) in order to observe when and if crosslinking of the gel would occur. After repeated 
experimentation, it was found that crosslinking of the HA occurred when the HA and Irgacure was 
pre-mixed and small amounts of the mixture was exposed to UV. HA was used as the hydrogel 
because the experiment laid the basis for a system that delivers NSCs to traumatic injury sites such 
as the brain. HA is a natural polymer found in the CNS with similar mechanical properties to brain 
tissue. HA also has anti-inflammatory properties, making it better fit for the experiment when 
compared to other natural polymers such as chitosan and alginate. Photocrosslinking was used 
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instead of chemical because the catalysts used in chemical crosslinking can be toxic to cells. 
Irgacure 2959 was used as the photoinitiator because it is highly efficient and is especially suited 
for use in acrylate-based systems. Although Irgacure is cytotoxic, it is less so than the chemical 
crosslinking catalysts. 
There were several device design options to choose from. Both T-junction and flow-focus 
devices were suitable for the experiment because they have the capability to generate 
monodisperse particles and to form microgel spheres of different sizes. Between the two, a flow-
focus device was used because flow-focusing devices have been shown to produce a more 
consistent microgel sphere size (Casquilas, 2015). Several flow-focus devices were used in testing: 
a straight-channel device with a collection chamber, a straight-channel device with no collection 
chamber, a serpentine device with a collection chamber, and a serpentine device with no collection 
chamber. The device that best suited the experiment was the serpentine device with no collection 
chamber. Its longer channel length allowed for the microgel spheres to have extended UV exposure 
for crosslinking. Having no collection chamber reduced the risks of the spheres coalescing.  
All of the design parameters were chosen with the goal of creating microgel spheres 
between 50 and 70 μm. This size was desired so that multiple cells could be encapsulated in a 
single sphere. Two solutions were pumped into the microfluidic device: an oil mixture and a 
hydrogel mixture. At first the oil mixture contained mineral oil and 2% Span 80 surfactant. The 
surfactant was used to prevent coalescence. The hydrogel mixture contained 0.75% HA, 0.5% 
Irgacure, and cells. After experimentation, the Irgacure was moved to the oil mixture to reduce the 
cytotoxicity to the cells, the volume percent of Span 80 was increased to 5% because coalescence 
of the spheres was observed with 2% Span 80, and dye was added to the oil mixture to help with 
visualization.  Solvent blue was used as the dye because it completely dissolves in solution unlike 
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other dyes that can form particles in solution. The final mixture components were mineral oil, 
0.5% Irgacure, 5% Span 80, and 0.05% Solvent Blue for the oil and 0.75% HA and cells for the 
hydrogel mixture. 
Many flow rates were tested in order to find the rates that induced sphere formation of the 
desired size. By experimenting with different flow rates, it was found that setting the flow rate of 
the HA to 25 μl/hr and the flow rate of the oil to 50 μl/hr produced microgel spheres, however the 
spheres were larger than desired. It was later found that a flow rate of 250 μl/hr for the oil mixture 
and 50 μl/hr for the hydrogel mixture created spheres in the correct size range. 
In order to confirm that the size of the microgel spheres was in the desired range, a size 
distribution was created by measuring and plotting the microgel sphere sizes of 360 spheres. The 
size distribution, shown in Fig. 6, displayed that most of the microgel spheres were in the desired 
range. In addition, the average sphere diameter was calculated to be 64.9 ± 6.4 μm, which was 
within the desired sphere size of 50-70 μm.  
Two different methods of exposing the microgel spheres to UV were executed in order to 
determine the best way to crosslink the microgel spheres. One method used a platform UV lamp 
and the other used a handheld UV lamp, both with a 365 nm wavelength and 3.8 mW voltage. It 
was found that when the device was put under the beam of the handheld UV lamp, crosslinking 
occurred. This technique was later revised to the device being taped down on top of the handheld 
UV lamp so that the channel of the device had more direct exposure to the UV.  
After flow rates that produced microgel spheres were found, cells were added into the HA 
to test if the cells could successfully be encapsulated in the microgel spheres. Three different cell 
types were used: Jurkats, pc 12, and U87MG cells. The cell types were used due to the fact that 
they were readily available. Jurkats had the added benefit of being easy to culture and U87MG 
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cells, a type of green-fluorescing protein, simplified the visualization of cell encapsulation by 
fluorescing green.  After collecting the microgel spheres, live/dead staining was performed, and 
fluorescence and brightfield microscopy was performed on a section of the collection. The Jurkats 
and pc 12 cells were stained with calcein, a stain that stains live cells green, and ethidium 
homodimer, a stain that stains dead cells red.  The U87MG cells were stained only with the 
ethidium homodimer.  Fig. 7. is an image of cell encapsulation within a microgel sphere. An 
overlay of fluorescent live and dead U87MG cells with the brightfield image is shown. Dead cells 
and cells outside of the microgel sphere are observed because of the extra time taken during the 
experimentation process to troubleshoot the flow through the device. 
 
Fig. 6. Size distribution of microgel spheres. 
Size distribution of the microgel spheres showed that the average sphere diameter was 64.9 ± 6.4 
μm, which was within the desired sphere size of 50-70 μm. 
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Fig. 7. U87MG cells, cell encapsulation in a microsphere. 
Chapter 5 – Final Design and Verification 
The serpentine design exposed the microgel spheres to the ultraviolet light for a longer 
time period than the straight channel inducing photocrosslinking. The serpentine design for the 
microfluidic device was chosen over the straight channel design because it allowed for more fully 
crosslinked microgel spheres. Our microfluidic design did not include a collection chamber in 
order to prevent coalescence of the microgel spheres within the chamber. Also a collection 
chamber was not included to allow for easier transport of the microgel spheres out of the device. 
A flow-focusing junction was chosen for our final design over a T-junction because the flow-
focusing design has been seen to form monodisperse microgel spheres more consistently than the 
T-junction. 
 Originally the two solutions flowing into the two inlets of the device contained Irgacure, 
hyaluronic acid, and cells in one solution with the mineral oil and surfactant in the other. This was 
improved by moving the Irgacure into the mineral oil and surfactant solution in order to reduce 
Project BME-AJ1-1401 
44 
 
cell toxicity. The final solution of the Irgacure, mineral oil, and surfactant solution contained 
mineral oil, 0.5% Irgacure, 5% Span 80, and 0.05% solvent blue. The final solution for the 
hyaluronic acid and cells contained 0.75% HA and cells. Flow rates were determined for each of 
the solutions through hyaluronic acid in order to attain microgel spheres with a diameter of the 
desired size range between 50-70μm. The flow rate determined for the Hyaluronic acid and cells 
solution was 50 μl/hr and the flow rate determined for the surfactant, Irgacure, and mineral oil 
solution was 250 μl/hr. 
 
Fig. 8. Experimental Set-up 
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Chapter 6 – Discussion 
6.1 – Gelation Testing 
The first test completed for this project was an attempt at achieving hydrogel gelation 
within a 24 well plate. The goal behind this test was to observe gelation of the hydrogel at a visible 
scale outside of the device. These tests were done to ensure that the device would not be run for a 
long period of time, only to learn that the hydrogel didn’t form all along. The belief was that the 
effect of the plate would be negligible on UV blocking, as would the glass plate used for the device. 
Much of the initial period was spent experimenting with different ratios of hyaluronic acid 
and irgacure. Different ratios of 0.75% HA and 0.5% w/v irgacure were tested to determine which 
mixture delivered the best gelation results. Experiments that increased the amount of both the 
irgacure and HA in the solution resulted in no gelation through December 2nd. 
The other factor that was considered was total volume in the well plate, specifically, the 
height of the gel in the plate that was exposed to UV. The more gel solution in the plate at a time, 
the more difficult it will be to cause the solution to form into a hydrogel. As seen in Chapter 5, 
most of the microgel spheres formed in the device had a diameter of ~70 μm. Since the diameter 
of the well plate was 6.5 mm, a height of 70 μm would be achieved in the 24 well plate by inserting 
a volume of just 2.32 μL. Smaller amounts of the solution were used in the well plate as the tests 
proceeded. 
In the end, it was determined that the core of the issue was the procedure used to prepare 
the hydrogel. The steps necessary to prepare hyaluronic acid hydrogel are very exact, and must be 
followed precisely. Deviations in the pH and procedure time can sabotage a batch of hyaluronic 
acid. Once the process for HA formation was refined, gelation results improved significantly. 
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Hydrogel formation was achieved using a combined HA/irgacure solution a 20 μL. Since this 
volume was significantly larger than the microgel spheres, the experimental process could move 
forward. 
 
6.2 – Microgel Sphere Formation 
Optimization of the microgel sphere formation process was another major task. Many 
issues can arise during this process that had to be accounted for. Many flow rates will not allow 
for microgel sphere formation in the device. The HA may flow out of the device in a stream, or in 
some cases the HA will be pushed back into the syringe by the oil flow. In addition, coalescence 
of the microgel spheres within the device is a major issue that can disrupt their formation. This 
issue led to the removal of the collection chamber from the device, since this is where much of the 
coalescence occurred. One side effect of the ultraviolet crosslinker is hydrogel formation at the 
inlet, which blocks the flow of microgel spheres through the device. When all of these issues were 
prevented, testing can focus on optimizing the size consistency of the microgel spheres. 
Determining the flow rate for the device inlet is a balancing act between a desire for 
efficiency and the need for stability. Running the device too fast can cause issues with microgel 
sphere formation at the inlet, and increases the risk of coalescence in the outlet tubing. However, 
the device is able to form consistent microgel spheres at a rapid rate when operated correctly. Good 
microgel sphere formation occurred by running the HA at 50 μL/hr and the oil at 250 μL/hr. It was 
observed that microgel sphere size is determined by the ratio of HA rate to oil rate. The higher the 
oil rate was compared to the HA rate, the smaller the microgel spheres were. 
Another issue that occurred in the process was gelation at the inlet. It was initially believed 
this to be the result of the ultraviolet light causing crosslinking at the inlet of the device. To account 
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for this, the UV light was focused on the outlet of the tubing, directing it away from the inlet. 
Gelation at the inlet still occurred even with this change. This problem was eventually solved by 
altering the location of the irgacure. Initially, the irgacure was mixed in with the HA, and oil was 
ran on the other side. Putting the irgacure in with the oil instead of the HA remedied the problem. 
The device was able to generate consistent microgel spheres within the range of 55-80 μm 
diameter. Size consistency was important for the reliability and therapeutic efficiency of the 
device. To verify this, a high speed camera was used to capture the microgel formation process, 
and measured the diameter of the microgel spheres. A list of the data received from this test is 
available in Appendix B. 
 
6.3 – Cell Encapsulation 
Arguably the most important element of this project was the success in encapsulating cells. 
In order to measure cell encapsulation, a new system of imaging had to be developed. This method 
involved staining the cells with two chemicals, calcine, and ethidium homodimer. Calcine is a 
green stain, and is able to detect the presence of live cells in the solution. Ethidium homodimer is 
a red stain, capable of detecting the presence of dead cells in the solution. By using a fluorescence 
microscope, the solution could be imaged to observe for the presence of cells. These images would 
then be superimposed onto an image of the microgel spheres themselves, taken under a regular 
microscope. If the cells matched up with the microgel sphere boundaries, it was assumed that 
encapsulation was successful. 
The experiment on March 3rd was the most effective experimental run for cell 
encapsulation, both devices produced clearly visible cell encapsulation. U87 cells were 
encapsulated, with visualization of the encapsulation available in the image in the results section 
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of the paper (Chapter 5). For these, the oil was stained to help us discern where the cells wound 
up in the solution to ease the imaging process. 
For the March 17th and March 24th experiments, microgel sphere formation and gelation 
was observed but no encapsulated cells were found during encapsulation. It is possible that the 
cells were not adequately mixed into the HA solution. Cells could have sank to the bottom of the 
tube, and the experiment could have been stopped before the cells with the HA were flowed 
through the device. 
 
6.4 – Economic and Social Implications 
Economically, the project should not drastically increase the cost of spinal therapy. 
Compared to the cost of spinal cord therapy, the materials needed for this project are relatively 
inexpensive. Nevertheless, adding another element to the therapy would marginally increase the 
cost of the procedure. Materials and equipment would need to be purchased, and additional time 
would need to be spent running the equipment. The crucial question then for anyone attempting to 
incorporate this therapy into the surgical procedure, is whether or not the benefits of the project 
outweigh the additional cost. If this project can take a surgery that was previously impossible due 
to cell survival issues, and turn it into a feasible treatment, then the cost of the procedure would be 
justified. 
The project should have a low environmental risk factor attached to it. None of the 
chemicals used in the process are released into the environment because the process is ran in a 
controlled laboratory setting. The biggest environmental risk of the project to be controlled is 
biological waste disposal. The experimental procedure requires the disposal of unused cells, as 
well as media, hyaluronic acid, and oil, among other products. For this, it is crucial that the 
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laboratory running these procedures uses proper biohazard waste procedures to avoid chemicals 
from the lab entering the environment. 
This project is not a therapy in of itself, rather the process developed will be used in 
hospitals to develop materials used in spinal cord therapy. Commercialization of this project would 
likely occur through a private company, which would develop the equipment to be sold directly to 
hospitals for their use in surgical procedures. Patients would not likely see these sales firsthand, as 
they are usually done between businesses. However, the need to incorporate more equipment into 
the procedure would likely increase the cost of the procedure. 
As with most new medical technologies, this product would likely be more available in 
first-world countries such as the United States, Japan, and Western Europe, where hospitals can 
afford these devices. If the product can be used to make stem cell CNS therapy a more viable 
procedure, then stem cell CNS therapy would then become even more available in these developed 
countries than in other less developed countries. 
This project would improve the lives of patients with CNS trauma by improving the quality 
of the surgery they can receive. Since currently only 5-10% of implanted neural stem cells survive 
in current stem cell therapies, this project would make treatments that were previously unfeasible 
available for use. For the patients who would receive these surgeries, this project would of great 
benefit. However, this project could also pose health risks to patients. The biggest danger the team 
worries about in this is the risk of viral infection through the cells. In many cases, this could put 
the patient at risk of death. This risk however, is consistent with any type of cell based therapy, 
regardless of encapsulation. From this perspective, this project poses no additional risk to the 
patient. 
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Manufacturing of this project will likely be the single greatest challenge that any team faces 
in the development of this project for commercial use. The device designed through this project is 
capable of producing about 50 µl of microgel spheres an hour. This is just a prototype, and will 
need to be scaled up to produce enough microgel spheres to be useful in therapy. One possible 
solution would be to create a device that uses many PDMS devices to create enough microgel 
spheres for usage in therapy. 
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Chapter 7 – Conclusions and Recommendations 
At the conclusion of this project, a flow focus serpentine microfluidic device capable of 
producing microgel spheres within the desired size range (50-70µm diameter) was modified and 
developed. In addition, a protocol for cell encapsulation was refined through experimentation. This 
protocol includes the system set-up, device dimensions, flow rates, inlet solution concentrations 
and volumes, and number of cells. The successful encapsulation of U87MG cells into microgel 
spheres is proof of concept for future experimentation in applying microfluidics for transplanting 
viable NSCs, which has not yet been attempted. This microfluidic system shows promise for 
successful and high throughput cell encapsulation, but needs to be further developed before use as 
a cell therapy delivery mechanism. 
There are several recommendations to improve the process and increase success. First and 
foremost, the team recommends changing the angle in the device to allow for better flow and 
reduce clogging in the device. Throughout the project, the team encountered several setbacks due 
to device clogging. Experimentation with the different angles within the device may lead to a 
decrease in troubleshooting time and overall process time, which would increase cell viability. 
A minor but potentially beneficial recommendation is to use a UV light source with a 
smaller diameter. The team noticed occasional inlet clogging due to premature hydrogel 
crosslinking. The current set-up utilized a UV source that was wider than the desired region for 
crosslinking. Using a UV light source with a smaller diameter would decrease inlet clogging and 
allow for more control of light placement on the crosslinking channel. With decreased inlet 
clogging, the overall process time would decrease. 
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The team also recommends expanding the imaging protocol. The microgel spheres can be 
difficult to image for several reasons. First, the microgel spheres lose their shape when imaged 
with glass slides and covers slips and are not stationary when imaged in well plates.  In addition, 
a dimension of the spheres is lost with two-dimensional imaging systems. Bright field and 
fluorescence imaging serve as sufficient methods for determining if cells were encapsulated but 
don’t provide the exact placement of the cells within the microgel sphere. A layer by layer imaging 
approach could be used to better understand the placement of cells within the microgel spheres. 
Before this system can be used to encapsulate cells for in vitro or in vivo use, the team 
recommends creating a storage system and incorporating biomarkers. While the exact set-up and 
parameters of the storage system are undefined, it would have to maintain the microgel spheres 
integrity and cell viability. One of the main issues associated with NSC therapy is that only 5-10% 
survive host immune response and inflammation. Biomarkers and bioactive molecules should be 
incorporated into the hydrogel to increase cell viability. In particular, the Fas ligand can be attached 
to the hydrogel backbone through the thiol groups. The Fas ligand can bind to immune cells and 
induce apoptosis, thereby increasing cell viability. 
A microfluidic system was created to encapsulate cells in to microgel spheres. Although 
this system and corresponding protocols require further optimization and experimentation, it 
shows promise. Once optimized, this system can be applied not only to encapsulating NSCs for 
neurological cell therapy, but also to other cell types. This technology has the potential to 
revolutionize current stem cell therapy practices. 
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Appendix A: Experimental Protocols 
Silicon Master Formation (Soft Lithography) 
1. Dehydration Bake 
a. Turn on the blower and light on the hood. Let it run for a few minutes before 
working inside. 
b. Power on the hot plate in the clean hood. Ensure the hotplate surface is clean. 
c. Set the temperature to 120 °C.  
d. Place a clean new wafer onto the hotplate surface. The whole wafer should 
completely fit on the hotplate surface so that heat can conduct evenly to the wafer. 
e. Once the plate reaches the desired temperature, heat for 5 min.  
f. Carefully remove from the hotplate with wafer tweezers and allow to cool to 
room temperature. The wafer is now ready for the next procedure. 
2. Spin-coating 
a. Turn on the two 7" hotplates. 
b. Set the left one to 65 °C and the right one to 95 °C. 
c. Set the spin program according to the description below 
i. The first step is a slow ramp to 500 rpm at 100 rpm/s and is designed to 
slowly spread the resist across the wafer. The second step spins faster to 
determine the final resist film thickness. Change the spin speed to account 
for different resist thickness 
d. Remove the spin-coater lid and verify the presence of a foil liner. If the foil is not 
present, line the bowl with foil to catch photoresist that is removed from the wafer 
during spinning. Ensure that the bowl periphery is covered above the height of the 
chuck and wafer, and also completely covering the bottom to the chuck. Rotate 
the chuck and ensure that the foil does not touch the chuck or impede rotation. 
e. Turn on the nitrogen supply, by opening the main tank valve. Ensure an output 
pressure of 60-70 psi.  
f. Make sure that the wafer is clean and dry. Visible dust on the wafer can be 
removed by gently blowing the wafer using the nitrogen gun. 
g. Position the 4" wafer alignment tool against the chuck, and place the wafer on the 
chuck aligning to the marks on the alignment tool. 
h. Before removing the alignment tool, turn on the vacuum. The wafer should now 
be held down on the chuck. 
i. Test your alignment by beginning the spin program. The wafer should wobble 
less than 5 mm.  
j. Ensure the wafer is centered and the spin-coater is programmed and ready to spin. 
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k. Pour approximately 8-10 mL of resist onto the wafer in one continuous motion, 
with the tube far enough to avoid contact with the wafer but close enough to 
prevent thin filaments of resist from forming: about 1 cm. Once the resist blob 
covers about 5cm diameter, quickly move the tube toward the edge while tilting 
the tube upwards and twisting to prevent drips on the outside of the tube.  
l. Start spin coating. The spin coating process takes about 1 minute. The spinner 
will stop automatically when spin coating is completed. 
m. Verify that the photoresist has been uniformly coated. If striations and streaks are 
observed, the spin coating was not successful. Some causes may include: 
i. dust particles on the surface (clean it better), 
ii. bubbles in the photoresist (heat the resist tube to 40-50 °C in a water bath 
to remove them; see resist datasheet for more information) 
iii. insufficient resist volume applied 
n. Release the chuck vacuum. 
3. Prebake (Soft Bake) 
a. Transfer the wafer from the spinner chuck to the 65 °C hotplate. Set the timer to 3 
minutes and cover the wafer with a foil tent. 
b. Transfer the wafer from the 65 °C hotplate to the 95 °C hotplate. Set the timer to 
9 minutes and cover the wafer with a foil tent 
c. Return the wafer to the 65 °C hotplate for 3 minutes, covered, then transfer it to 
the clean hood to cool to room temperature.  
4. UV exposure 
a. Turn on the UV exposure unit. 
b. Unlock the drawer of the UV exposure unit. If there is a wafer or mask present, 
remove them. Place the 4"x 5" glass slide on the tray and wave near the door 
sensor to close it. 
c. Calibrate the UV intensity. It should display about 23.4 mW/cm2 through the 
glass plate.  
d. Program the desired exposure duration and intensity, in our case 14 s. 
230
𝑚𝐽
𝑐𝑚2
 𝑥 1.5
23.4 
𝑚𝑊
𝑐𝑚2
= 𝐸𝑥𝑝𝑜𝑠𝑢𝑟𝑒 𝑇𝑖𝑚𝑒 (𝑠) 
e. Start the exposure. Verify that the countdown timer begins at the proper duration.  
f. The exposure will end automatically and alert with a loud beep. Remove the glass 
slide if present. 
g. Transfer the room temperature, resist-coated wafer to the UVKUB tray, centering 
it in the circular pattern. 
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h. Observe the position of any defects in the resist layer. Try to rotate your 
photomask such that these defects are removed during development. 
i. Cut out the photomask circle using scissors. Ensure it is free of dust, and gently 
wipe with a lint-free cleanroom wipe or blow with the nitrogen gun if necessary. 
j. Place the photomask over the resist-coated wafer and orient it such that any 
defects will be removed during development. 
k. Place the 4" x 5" glass slide over the wafer and mask to keep it flat and in direct 
contact. When you are satisfied with the mask orientation and glass plate 
placement, close the door. 
l. Run the previous exposure program. Verify the correct exposure intensity 
m. The exposure will end automatically and alert with a loud beep. The drawer opens 
automatically. 
n. Gently lift the glass slide with wafer tweezers and set aside. Gently lift the 
photomask with wafer tweezers and set aside.  
o. Observe the resist surface. At this point, no pattern should be easily visible. If it 
is, the exposure time was too long. 
5. Post-Exposure Bake (PEB) 
a. Transfer the wafer from the UV exposure unit  to the 65 °C hotplate in the fume 
hood. Be sure to place your hand underneath as you move the wafer so it doesn't 
drop. Set the timer for the desired time at this PEB temperature (3 minutes). 
b. Observe the resist surface. With ideal exposure, the mask pattern will become 
slightly visible in 5-30 s. Cover with a foil tent. 
c. Transfer the wafer from the 65 °C hotplate to the 95 °C hotplate and cover. Set 
the timer for the desired time at this temperature (9 minutes). 
d. Return the wafer to the 65 °C hotplate for 3 minutes, then transfer it to a 
cleanroom wipe on the work surface to cool to room temperature. At this point, 
the mask pattern should be clearly visible. If not, exposure and/or baking times 
were too short. 
6. Development 
a. Ensure the glass dish is clean, clean if necessary. Pour developer in the dish to 
about 0.5-1 cm depth. 
b. Immerse the wafer in developer and gently slosh/agitate, taking care not to splash 
developer out of the dish. Set a timer for 7-10 minutes. 
c. Observe the wafer periodically. Bare Si regions will become visible after ~30s - 1 
min. The resist at the edge is thicker than in the center, and therefore tends to be 
the last part to dissolve away. 
d. When all resist appears dissolved, remove it from the developer bath with wafer 
tweezers and run under a gentle stream of water in the hood sink.  
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e. After both front and back sides are rinsed in water, dry both sides with the 
nitrogen gun.  
f. Inspect the wafer for any cracks or other issues. Perform a final cleaning 
development by holding the wafer with tweezers horizontally over the dish and 
squirting a small amount of fresh developer on the wafer. Gently slosh side-to-
side for about 15s. Rinse with water and dry with a nitrogen gun. 
7. Post-bake 
a. Place the developed wafer on a hotplate at no more than 65 °C. 
b. Set the ramp rate to 6 °C/min or 360 °C/hr. Set temperature to 150°C. Set the 
timer for 45 minutes. Set the hotplate to automatically turn off then the timer 
ends. Cover with a foil tent. 
c. The hotplate will slowly ramp up to 150°C over about 15 minutes, maintain 
temperature for ~30mins, then turn off and slowly return to room temperature. 
This will take around 1 hr total. 
d. After the wafer has returned to room temperature, inspect the wafer again and 
verify that surface cracks have disappeared. Document selected microscope fields 
with a camera. 
 
PDMS Device Formation 
1. Create a 10:1 mixture of PDMS, using 50 g of the PDMS base, and 5 g of the PDMS 
curing agent 
2. Stir the mixture for 5-10 minutes, being sure to mix the edges in addition to the center. 
Make sure the full solution is mixed by lifting PDMS from the bottom to the top 
3. Place the PDMS mixture into the vacuum chamber for 45 minutes, to remove any air 
bubbles. 
4. Pour the PDMS mixture into the device mold. If any air bubbles are present, move them 
away from the device 
5. Leave the device mold in the oven at 65 °C overnight, for at least twelve hours. 
6. Remove the device mold from the oven.  
7. Use a razor blade to cut the devices out of the PDMS mold. 
8. Punch holes through the inlets and outlets of the device. This can be done efficiently 
using these steps. 
a. Place a piece of scotch tape on the side of the device with the engravings 
b. Use a sharpie to draw in the locations of the inlets and outlets onto the tape 
c. Use a holepuncher to pierce into the inlets through the tape side going all the way 
through the device. Remove the scrap from the holepuncher before removing 
9. Plasma bond the PDMS device to the glass slide. This can be done effectively using these 
steps. 
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a. Place the PDMS device onto the base slide with the engravings facing up. 
b. Place the glass slide to be used onto the base slide next to the PDMS 
c. Insert the base slide into the plasma bonder. Close the door and form the vacuum 
seal 
d. Turn the plasma bonder on. Expose the materials to the plasma for 30 seconds 
e. Remove the materials from the plasma bonder. As quickly as possible place the 
PDMS engraving side against upward facing side of the glass slide 
f. Hold the PDMS against the glass slide for at least two minutes. Make sure the 
entire PDMS is connected to the glass slide 
10. Place the PDMS device into the oven at 80 °C for 48 hours.  
11. Once the PDMS is removed from the oven, it is ready to be used. 
 
Hyaluronic Acid Formation 
1. Prepare 1% w/v solution of high MW HA 
a. Dissolve 0.25 g of high MW HA in 25mL 0.01M NaOH solution with a pH of 
12.5 
b. Place pure HA mixture on rotisserie shaker in room temperature overnight or for 
4 hours for complete dissolution 
2. Acrylate HA polymer with divinyl sulfone (DVS) 
a. Add 597 µl of DVS 
b. React mixture under continuous vortexing for 5 minutes and on the rotator for 15 
minutes, protected from light by aluminum foil 
c. The solution should be at pH 12 
3. After 20 minutes, quench the reaction with 1.5M HCl 
a.  The volume of HCl added will depend on the initial pH of the solution. After 
quenching, the solution should be at pH 5 (pH 5.0-5.2) 
b. Note: About 150-300 µl may be added. Add in slowly and consistently check pH 
4. Dialyze with 25k dialysis bags against diH2O in the cold room 
a. Change water bath every 4 hours to remove excess DVS and allow dialysis to 
occur in clean water 
5.  After 48 hours, separate 25 mL mixture into 3 separate opaque 50 mL conical tubes. Seal 
with parafilm, and store in -80 °C to freeze. Sample must be frozen prior to lyophilization 
6. After 48 hours, the solution must be lyophilized 
a. Start the lyophilizer, and wait 30 minutes for equalization 
b. During equalization, seal tubes with frozen HA using kimwipes and rubber band. 
Place in jar and lyophilize 
c. When finished, place the lyophilized HA samples in the freezer in the dessicater, 
protected from light. 
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Hyaluronic Acid Reconstitution 
1. Dissolve acrylated HA in PBS 
a. Pour 10 mL of PBS into a 15 mL conical tube 
b. Add 0.075 g acrylated HA into the PBS solution 
c. Vortex the solution until all of the acrylated HA is dissolved 
𝑀𝑎𝑠𝑠 (𝑔) =  
𝑤
𝑣 %
100
 𝑋 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝐿) 
𝑀𝑎𝑠𝑠 =  
0.75 𝑤𝑡%
100
 𝑋 10 = 0.075 𝑔 
Oil, Surfactant, Irgacure and Dye Formation 
1. Add 10 mL of mineral oil to a 15 mL conical tube 
2. Add 0.5 mL of surfactant to the solution (5% oil volume) 
3. Add 0.05 g of Irgacure 2959 to the solution (0.5% oil volume) 
4. Add 0.005 g of solvent blue to the solution (0.05% oil volume) 
 
Cell Culture 
1. Perform trypsinization, (if necessary) 
2. Pipette cell culture into a 15 mL conical tube 
3. Spin down in centrifuge 
4. Resuspend cell culture in media 
5. Count the cells using the hemacytometer 
a. Insert 10 µl of the cell suspension into the hemacytometer 
b. Count the total cells in the upper two, middle, and lower two grids on the 
hemacytometer 
# 𝑐𝑒𝑙𝑙𝑠
5 𝑏𝑜𝑥𝑒𝑠
 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑥 10,000 = 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠/𝑚𝐿 
6. Spin the cells in the centrifuge for 5 minutes 
7. Resuspend the cells in a 1 mL of media 
8. Aliquot 1 mL of reconstituted HA into the test tube 
9. Add the cells to the HA solution 
10. Resuspend the cells using the pipet aid 
11. Vortex the solution for 30 seconds 
12. Pour cell solution into the syringe 
13. Make sure no bubbles are present in the tube 
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 Apparatus Setup 
1. Place PDMS device under a microscope attached to a computer with imaging software 
2. Add the cell/HA solution to syringe #1 
3. Add the oil mixture to syringe #2 
4. Place tubing into an aliquot tube containing cell media, and connect the other end of the 
tube to the device outlet 
5. Connect the syringe tubing to the respective inlets on the PDMS device 
 
Microfluidic Device Operation 
1. Prior to the experiment 
a. Set diameter to 8.76 mm 
b. Set syringe #1 flowrate to 50 µl/hr 
c. Set syringe #2 flowrate to 250 µl/hr 
2. Start both syringes at the same time 
3. Wait until droplets are forming inside of the device 
a. If droplets are not forming after 10 minutes, increase both flow rates and then 
decrease to the specified values in step 1 
4. Once droplets are being formed, move device from the microscope to the UV light. 
5. Collect the droplets in the media within tube 
6. Proceed with this for 45 minutes 
 
Droplet Imaging 
1. Stain the droplets using the following steps 
a. Spin down in centrifuge for 2min. at 1000rpm 
b. Aspirate the top layer of media and oil 
c. Perform live/dead staining using the appropriate amount of stain 
2. Place cells under microscope to collect fluorescent, brightfield and the overlay of the 
fluorescent and brightfield images 
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Appendix B: Size Distribution Raw Data 
Microgel spheres formation was recorded using a camera 
 
Fig. 9. Microgel spheres being formed 
Microgel sphere diameters were measured using ImageJ.  
Droplet Area Mean Min Max Diameter 
(µm) 
Average 
Diameter 
(µm) 
Diameter 
Median 
(µm) 
STDEV 
1 155.204 127.516 122 130.333 52 64.9295766 64.119 6.407603 
2 186.245 124.937 116.333 129.309 63.252    
3 170.724 126.376 115.111 130.333 59.429    
4 170.724 125.938 117.407 130 59.429    
5 162.964 126.606 113.333 130.88 54.841    
6 178.485 118.672 108.333 124.853 62.263    
7 170.724 120.129 103 129.496 59.429    
8 170.724 116.456 99.566 124.566 59.429    
9 186.245 118.348 102.556 124.984 63.143    
10 194.005 134.947 122.111 139.889 66.857    
11 170.724 139.468 128.815 145.086 59.429    
12 170.724 140.824 130.444 145.46 59.429    
13 170.724 138.437 123.889 145.81 59.429    
14 162.964 137.362 129.222 143.889 54.841    
15 201.765 130.89 111.778 141.932 69.389    
16 186.245 126.155 110.704 132.089 63.143    
17 170.724 124.546 111.63 130.464 59.429    
18 194.005 122.324 111 129.667 66.857    
19 194.005 129.301 119.778 132.815 66.857    
20 217.286 128.786 118.593 134.667 74.286    
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21 225.046 128.94 116.889 135.481 78    
22 194.005 128.582 118.778 132.889 66.857    
23 170.724 128.514 124.267 136.896 58.728    
24 155.204 125.834 117.889 130.064 54.081    
25 155.204 126.574 107.444 135.135 52    
26 162.964 126.153 115.333 130.667 55.714    
27 162.964 120.36 106.778 125.778 55.714    
28 217.286 129.009 119.704 133.333 74.286    
29 225.046 133.701 119.889 139 78    
30 225.046 132.697 117.222 139.889 78    
31 201.765 131.865 121.222 136.016 70.571    
32 209.526 128.667 117.333 133.667 71.446    
33 162.964 127.662 121.074 132.422 55.838    
34 186.245 122.737 110.889 127.457 63.143    
35 155.204 132.58 118.667 136.667 52    
36 194.005 121.049 103 131.778 66.857    
37 201.765 134.871 122.667 141.031 70.571    
38 217.286 134.235 121.63 140.314 74.286    
39 186.245 133.792 120.333 143.667 66.857    
40 201.765 134.611 120.333 143.213 70.669    
41 162.964 131 121.111 142.24 55.714    
42 194.005 129.425 117 134.926 66.857    
43 170.724 124.285 115.963 128.086 59.429    
44 225.046 124.395 106.667 132.111 78    
45 162.964 127.354 110.889 134.667 55.714    
46 170.724 130.637 124 135.644 59.545    
47 201.765 133.028 120.333 137.84 70.571    
48 194.005 132.671 121.444 140 66.857    
49 217.286 128.682 120.185 136.237 74.286    
50 186.245 128.303 120.222 136.968 63.903    
51 186.245 127.469 115.889 131.149 63.252    
52 186.245 124.881 115 129.841 63.578    
53 155.204 126.771 114 131.222 52    
54 170.724 128.076 113.037 133.065 59.429    
55 186.245 140.895 130.296 145.628 63.143    
56 217.286 140.79 125.444 147.435 74.286    
57 162.964 141.344 132.63 144.926 55.714    
58 170.724 138.065 128.333 144.841 59.429    
59 186.245 134.483 125.333 142.793 63.252    
60 194.005 133.863 117.296 141.099 66.96    
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61 186.245 131.364 114.889 138.333 63.143    
62 217.286 129.468 112.889 140.941 74.286    
63 170.724 131.086 119.519 135.709 59.429    
64 201.765 135.545 124.963 141.227 70.669    
65 170.724 140.932 126.222 146.111 59.429    
66 170.724 139.582 129.333 142.868 59.429    
67 194.005 138.351 126.333 143.444 66.857    
68 194.005 136.559 124.407 144 66.443    
69 209.526 132.812 114.444 139.201 72.118    
70 186.245 126.094 118.37 131.005 63.143    
71 186.245 126.006 111.778 134 63.143    
72 155.204 128.417 120.333 130.333 55.714    
73 194.005 143.587 130.333 149.222 66.857    
74 217.286 145.369 129.667 151.218 74.286    
75 225.046 143.318 132.889 151.556 78    
76 194.005 142.381 128.741 148.815 66.857    
77 186.245 144.68 131.012 149.82 64.119    
78 162.964 141.52 128.889 147.124 54.841    
79 217.286 134.946 118 142.736 74.379    
80 186.245 135.22 115.111 143.863 63.143    
81 170.724 131.614 118 138.102 59.429    
82 162.964 148.09 139.185 152.333 55.714    
83 201.765 147.797 132.444 153.867 70.571    
84 201.765 145.622 136.333 149.622 70.571    
85 201.765 144.61 127.556 150.853 70.669    
86 162.964 145.569 133.667 152.156 55.217    
87 170.724 143.861 128.407 149.026 59.429    
88 162.964 142.852 133 147 55.714    
89 186.245 134.493 115.63 140.929 63.143    
90 217.286 135.695 119.503 145.977 74.286    
91 194.005 140.403 122.741 146 66.857    
92 225.046 142.28 123.333 149.852 78    
93 194.005 142.404 128.333 148 66.857    
94 217.286 140.05 125.63 148.506 74.286    
95 186.245 139.867 127 147.013 64.867    
96 155.204 137.087 129.444 143.964 54.081    
97 162.964 132.869 120.111 138.778 55.838    
98 186.245 134.756 120.481 140.683 63.143    
99 170.724 125.794 112.778 134.287 59.429    
100 201.765 131.228 117.333 137 70.571    
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101 186.245 133.486 125.667 137.667 66.857    
102 186.245 132.941 125 137.729 63.143    
103 170.724 134.157 122.111 138.125 59.429    
104 170.724 130.108 123.001 136.125 58.019    
105 217.286 119.393 105.136 128.505 74.286    
106 201.765 125.926 107.556 133.333 70.571    
107 186.245 127.89 108 139 63.143    
108 194.005 123.249 109.37 130.037 66.857    
109 186.245 135.423 123.074 137.965 63.143    
110 217.286 141.757 123 149.34 74.286    
111 201.765 140.996 126.667 147.333 70.571    
112 194.005 140.699 126.037 145.926 66.857    
113 217.286 137.677 118.222 146.77 74.286    
114 178.485 137.068 125 143.047 60.919    
115 155.204 135.867 123 145 55.714    
116 186.245 134.284 122.37 144.527 63.143    
117 186.245 133.065 115.667 139.855 63.143    
118 186.245 135.531 125.259 137.778 63.143    
119 217.286 138.727 123.481 145.269 74.286    
120 186.245 140.861 126.667 147 66.857    
121 194.005 136.982 124.444 142.333 66.857    
122 155.204 135.506 125.556 139.547 52.528    
123 186.245 132.528 124.333 136.657 63.143    
124 186.245 131.052 111.037 140.667 63.143    
125 201.765 130.207 116.667 137.049 70.571    
126 194.005 126.679 117.037 132.222 66.857    
127 186.245 133.355 122.111 139.546 63.143    
128 217.286 133.07 123.481 137.487 74.286    
129 194.005 132.364 124 137.333 66.857    
130 186.245 133.386 122.667 137.667 63.143    
131 170.724 132.731 123.667 137.004 58.138    
132 186.245 126.937 110.333 132.027 64.119    
133 186.245 121.284 110.333 126.333 63.143    
134 186.245 126.806 119 130.333 66.857    
135 225.046 121.923 105.778 126.556 78    
136 201.765 149.962 135.333 154.88 70.571    
137 217.286 146.448 136.778 152.519 74.286    
138 217.286 147.097 134 155.025 74.286    
139 186.245 147.154 137.074 151.884 63.143    
140 170.724 145.462 132.333 153.159 58.728    
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141 201.765 141.282 131 147.641 68.488    
142 170.724 137.139 119.889 144.534 59.429    
143 194.005 138.76 126.852 144.926 66.857    
144 155.204 135.467 125 138.333 55.714    
145 194.005 139.664 130.815 144.778 66.857    
146 225.046 144.605 129 151.778 78    
147 217.286 140.761 130.259 147.955 74.379    
148 225.046 141.151 121.148 148.63 78    
149 194.005 138.664 129.63 146.663 66.443    
150 178.485 138.3 127.937 144.203 60.464    
151 155.204 137.348 121.778 142.251 52    
152 170.724 136.643 117.444 146.272 59.545    
153 194.005 132.141 116.519 138.741 66.857    
154 170.724 145.05 137 148.185 59.429    
155 201.765 148.453 137.074 154.8 70.571    
156 155.204 146.646 138.556 151.936 52    
157 170.724 145.855 137.778 151.333 59.429    
158 217.286 141.193 126.444 152.778 74.749    
159 170.724 142.447 132.519 148.112 58.728    
160 186.245 139.351 128.556 144.889 63.143    
161 186.245 138.767 123.778 145.565 63.143    
162 170.724 138.24 126.778 142.887 59.429    
163 194.005 134.902 124.444 139.333 66.857    
164 194.005 135.502 121.296 140.333 66.857    
165 217.286 131.813 117.593 136.436 74.286    
166 170.724 133.064 123.667 136.217 59.429    
167 170.724 128.467 121.556 136.172 58.019    
168 170.724 129.845 123.556 134.074 57.661    
169 217.286 120.056 105.095 128.951 74.286    
170 186.245 123.603 113 128.874 63.143    
171 201.765 118.184 109 123.28 70.571    
172 201.765 136.367 123.667 143.889 70.571    
173 170.724 139.669 128.222 143.333 59.429    
174 194.005 138.636 125 143.333 66.857    
175 170.724 137.493 124.889 142.185 59.429    
176 170.724 138.158 125.407 145.815 58.019    
177 217.286 129.356 114.667 140.444 74.286    
178 194.005 117.613 113.444 121.556 66.857    
179 201.765 130.215 114.444 138.667 70.571    
180 194.005 130.274 116.481 137.889 66.857    
Project BME-AJ1-1401 
68 
 
181 201.765 140.427 127.519 145.015 70.571    
182 186.245 142.922 133.889 146.319 63.143    
183 186.245 137.771 126.889 141.802 63.143    
184 170.724 141.834 131.111 144.937 59.429    
185 209.526 133.648 120.667 145.519 71.349    
186 178.485 133.94 122.667 140.41 60.006    
187 162.964 135.815 121.889 141.333 55.714    
188 194.005 132.338 122 138.222 66.857    
189 186.245 131.343 114.63 140.377 63.143    
190 201.765 142.406 130.556 146.773 70.669    
191 217.286 144.558 127.741 151.37 74.286    
192 217.286 142.296 127 147.333 74.286    
193 225.046 139.465 126.926 145.852 78    
194 170.724 138.501 127.704 144.259 58.728    
195 178.485 136.901 122.333 144.432 61.258    
196 217.286 133.142 113.667 144.086 74.286    
197 186.245 135.394 121.37 140.092 63.143    
198 170.724 132.156 121.926 138.683 59.429    
199 201.765 138.048 125.111 144.139 70.669    
200 201.765 140.468 127.556 148.907 70.571    
201 170.724 140.937 129.333 146.19 59.429    
202 201.765 137.115 121.667 144.57 70.571    
203 178.485 139.077 128.889 143.505 60.006    
204 155.204 133.151 123.333 137.801 54.081    
205 170.724 133.74 118.222 141.238 59.429    
206 170.724 131.88 118.556 139.423 59.545    
207 201.765 126.773 109.222 135.271 70.669    
208 201.765 138.052 125.556 145.004 70.571    
209 217.286 139.635 126.148 144.362 74.379    
210 170.724 141.681 136.111 144.725 59.429    
211 201.765 137.302 128 142.4 70.571    
212 170.724 140.352 124.444 145.985 57.661    
213 186.245 131.455 126.222 137.072 64.867    
214 162.964 133.19 125.222 138.444 55.714    
215 170.724 132.028 118.556 136.889 59.429    
216 194.005 128.467 111.889 136.074 66.857    
217 170.724 135.42 127.556 140.148 59.429    
218 201.765 138.816 128 143.693 70.571    
219 194.005 134.409 124 141.778 66.857    
220 186.245 134.44 123.519 141.167 63.143    
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221 155.204 135.276 126.667 141.852 53.568    
222 186.245 134.481 121.333 139.932 63.578    
223 201.765 128.417 110.667 139.098 70.571    
224 170.724 128.377 113.296 133.97 59.429    
225 194.005 123.982 106.222 132.111 66.857    
226 186.245 134.194 120.667 140.667 66.857    
227 201.765 138.821 121.185 147.594 70.571    
228 217.286 137.004 121.654 143.21 74.286    
229 194.005 136.991 124.333 142 66.857    
230 186.245 135.656 121.667 140.7 64.119    
231 162.964 132.157 118.222 139.667 56.574    
232 170.724 129.465 116.111 136.349 59.545    
233 186.245 127.028 114.556 134.043 63.143    
234 186.245 122.903 107.889 129.638 63.143    
235 194.005 137.502 124.667 141.333 66.857    
236 186.245 134.726 126.222 137.333 63.143    
237 201.765 134.819 122.778 142.719 70.571    
238 201.765 136.12 118.481 142.441 70.571    
239 178.485 132.442 121.889 138.442 60.919    
240 178.485 131.087 118.222 136.718 61.258    
241 201.765 129.027 113.333 140.84 70.571    
242 194.005 125.105 111.185 129.037 66.857    
243 186.245 121.703 112.889 129.884 63.143    
244 201.765 132.543 121.111 137.32 70.571    
245 162.964 136.868 125.222 141.667 55.714    
246 162.964 136.025 131.556 138.259 55.714    
247 217.286 132.612 121.074 137.606 74.286    
248 178.485 133.109 122.222 136.012 60.006    
249 162.964 129.886 122 133.693 56.574    
250 186.245 127.471 108.556 137.525 63.143    
251 194.005 124.548 109.037 130.63 66.857    
252 194.005 122.705 110.63 129.556 66.857    
253 217.286 137.015 124.519 140.962 74.286    
254 186.245 138.706 127.333 142.222 63.143    
255 186.245 138.644 122.259 143.314 63.143    
256 201.765 135.074 120.778 142.993 70.571    
257 194.005 133.449 116.444 140 67.779    
258 155.204 133.416 125.444 136.86 51.734    
259 194.005 129.093 109.926 137.741 66.96    
260 194.005 126.493 113 133.111 66.96    
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261 170.724 129.3 114.333 133.894 59.429    
262 217.286 131.12 117.593 136.041 74.286    
263 186.245 135.681 122.667 139.333 66.857    
264 186.245 137.292 127.333 140.412 63.143    
265 201.765 133.996 124.407 140.102 70.669    
266 209.526 131.642 123.037 138.325 71.349    
267 186.245 128.598 118.556 131.367 63.252    
268 170.724 124.961 118.778 128.762 59.429    
269 194.005 125.467 116.778 131 66.857    
270 170.724 126.476 113.519 131.37 59.429    
271 201.765 130.977 124.222 135 70.571    
272 194.005 133.236 122.111 137.889 66.857    
273 194.005 131.582 117.778 137.926 66.857    
274 225.046 130.605 121.556 136.111 78    
275 217.286 131.118 114.852 137.284 74.286    
276 155.204 132.615 123.333 137.953 53.568    
277 186.245 132.768 119 138.072 64.119    
278 201.765 124.821 108.667 132.667 70.571    
279 201.765 123.514 106.667 129.471 70.571    
280 170.724 130.201 118.667 136.473 59.429    
281 201.765 136.084 126.741 140.231 70.571    
282 217.286 138.892 123.556 145.686 74.286    
283 201.765 136.406 125 142.43 70.571    
284 194.005 137.596 123.593 143.593 66.857    
285 209.526 135.699 122.111 142.801 72.974    
286 162.964 131.186 120 138.444 56.574    
287 194.005 130.969 111.444 139.778 66.857    
288 217.286 131.077 110.852 138.951 74.286    
289 194.005 126.867 112.111 134.444 66.857    
290 186.245 135.98 123.519 139.7 63.143    
291 201.765 138.793 122.778 146.111 70.571    
292 194.005 137.469 122.222 144.444 66.96    
293 162.964 139.666 129.333 145.267 55.838    
294 162.964 132.008 119.148 144 56.696    
295 170.724 132.814 121.111 141.937 59.429    
296 162.964 126.273 113 132.37 55.714    
297 162.964 126.265 118.111 132.667 55.714    
298 186.245 136.405 121.815 142.725 63.143    
299 186.245 138.097 123.333 143.667 66.857    
300 170.724 138.598 128.333 143.238 59.429    
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301 201.765 136.85 125.519 142.535 70.571    
302 162.964 133.465 127.259 140.422 55.714    
303 194.005 133.391 123 138.667 66.857    
304 186.245 130.592 119.222 137.211 63.143    
305 170.724 128.165 118.926 133.259 59.429    
306 186.245 136.936 125 142.177 63.143    
307 217.286 137.439 126.667 141.556 74.286    
308 194.005 135.129 123.556 139.889 66.857    
309 170.724 134.952 127.519 138.882 59.429    
310 178.485 133.713 119.667 138.648 60.006    
311 162.964 130.617 118.111 134.556 56.818    
312 170.724 131.385 118 134.986 59.429    
313 186.245 130.671 120 134.855 63.143    
314 170.724 125.749 109.889 130 59.429    
315 217.286 134.011 123.556 137.54 74.286    
316 194.005 137.514 123.778 144.259 66.857    
317 194.005 139.196 127.778 144.333 66.857    
318 194.005 136.027 121 143 66.857    
319 186.245 135.83 127.778 142.464 64.867    
320 186.245 122.604 110.013 135.166 63.034    
321 186.245 129.76 112.037 135.181 63.252    
322 194.005 126.191 118.889 130.111 66.857    
323 194.005 125.475 111.667 134.741 66.96    
324 201.765 134.616 118.667 138.633 70.571    
325 217.286 137.787 119.889 143.001 74.286    
326 186.245 138.224 127.333 141.604 63.143    
327 186.245 137.215 123.704 142.567 63.143    
328 217.286 135.167 120.259 142.223 74.656    
329 170.724 132.522 121 142.458 59.891    
330 186.245 128.896 111.481 135.628 63.143    
331 194.005 128.067 111.889 134.333 66.857    
332 201.765 126.035 108.704 132.067 70.669    
333 194.005 133.293 124.444 136.667 66.857    
334 217.286 137.273 125.333 142.731 74.286    
335 186.245 136.223 122.074 141.333 63.143    
336 194.005 135.641 128.333 140.111 66.857    
337 217.286 133.298 119.556 140.809 74.286    
338 178.485 131.744 126 138.746 61.482    
339 217.286 128.673 112.926 136.444 74.286    
340 155.204 129.251 122 134.962 52.528    
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341 162.964 126.122 112.222 131.111 55.714    
342 217.286 131.82 120 137 74.286    
343 170.724 139.698 131.667 144.799 59.429    
344 170.724 136.402 127.667 140.827 59.429    
345 201.765 135.651 123.963 144.222 70.571    
346 186.245 130.361 117.111 141.493 63.252    
347 155.204 134.276 124.889 140.76 52    
348 194.005 128.058 111 134 66.857    
349 162.964 130.205 120.074 135.148 55.714    
350 194.005 121.591 112.667 129.444 66.857    
351 194.005 133.354 118.333 142.815 66.857    
352 186.245 135.098 121 140.28 63.252    
353 194.005 132.867 126.222 135.593 66.857    
354 194.005 133.157 121 139.074 66.857    
355 194.005 129.386 117 139.519 66.131    
356 201.765 128.331 117 138.311 70.571    
357 194.005 125.778 112.926 130.444 66.857    
358 170.724 124.397 114 132.667 59.429    
359 194.005 122.701 112.593 129.556 66.857    
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Appendix C: ABET Requirements 
3. An ability to design a system, component, or process to meet desired needs within realistic 
 constraints such as economic, environmental, social, political, ethical, health and  safety, 
 manufacturability, and sustainability (ABET 3c) while incorporating appropriate 
 engineering  standards (ABET Criterion 5) (need to assess each of these separately, but 
 since ‘or’ and “such as” not all need to be met separately). 
i) multiple realistic constraints (economic, environmental, social, political, ethical, 
 health and safety, manufacturability) – pages 33-34, 50-52  
ii) appropriate engineering standards - pages 36-47 
4. An ability to function on multidisciplinary teams (3d). pages 6-7 
6. An understanding of professional and ethical responsibilities (3f) 
i) Professional – pages 7, 50-52 
ii) Ethical – pages 12 
7. An ability to communicate effectively (3g). pages 1-75 
8. The broad education necessary to understand the impact of engineering solutions in a global, 
 economic,  environmental, and societal context (3h). (both economic AND 
 environmental need to be addressed)    
i) Economic – pages 50-52 
ii) Environmental – pages 50-52 
10. A knowledge of contemporary issues (3j). pages 9-12 
 
